about
Targeted pharmacological treatment of autism spectrum disorders: fragile X and Rett syndromesDevelopmental specification of metabolic circuitryEffect of 30 Hz theta burst transcranial magnetic stimulation on the primary motor cortex in children and adolescents.14-3-3ζ deficient mice in the BALB/c background display behavioural and anatomical defects associated with neurodevelopmental disordersIncreasing our understanding of human cognition through the study of Fragile X Syndrome.Investigation of genes important in neurodevelopment disorders in adult human brain.Reduced phenotypic severity following adeno-associated virus-mediated Fmr1 gene delivery in fragile X mice.Immunohistochemical visualization of hippocampal neuron activity after spatial learning in a mouse model of neurodevelopmental disorders.Engrailed-2 (En2) deletion produces multiple neurodevelopmental defects in monoamine systems, forebrain structures and neurogenesis and behaviorAutism spectrum disorders: from genes to neurobiologyEnhancement of GluN2B Subunit-Containing NMDA Receptor Underlies Serotonergic Regulation of Long-Term Potentiation after Critical Period in the Rat Visual Cortex.Highly specific structural plasticity of inhibitory circuits in the adult neocortexNeuronal plasticity and antidepressant actions.Progress toward treatments for synaptic defects in autism.The developmental stages of synaptic plasticity.Neural and behavioral epigenetics; what it is, and what is hype.Epigenetics and child abuse: Modern-day Darwinism--The miraculous ability of the human genome to adapt, and then adapt again.Lessons learned from studying syndromic autism spectrum disorders.Pharmacological profile of brain-derived neurotrophic factor (BDNF) splice variant translation using a novel drug screening assay: a "quantitative code"Making connections.Nimodipine activates TrkB neurotrophin receptors and induces neuroplastic and neuroprotective signaling events in the mouse hippocampus and prefrontal cortex.Nucleotide Excision Repair: From Neurodegeneration to Cancer.
P2860
Q27023257-6F12A43F-00C8-4CEF-B1A3-D89F2791AA8CQ30373177-49EA8A6E-94CD-41D3-9AFD-407EBBDDE133Q30416874-6442B1FA-62CC-46BB-AFA6-541D7BBCCE0EQ30658834-090B2AEB-908E-44D9-AAF3-92766AA296A8Q34435526-04E87D6F-C2A5-45BB-A07B-FA709AD5433DQ34485973-00C8BC60-90A5-49BC-8ED0-9E3B184C446DQ34499370-EA6B2D53-6CBA-4B7C-8A20-91A3DF223636Q35974605-A77C8C67-0F43-4858-83CD-B4688F97BE38Q36089383-55FFDDBE-D480-4F9D-821B-93E24E969A54Q36101188-FA39BEC7-F932-4291-9F87-1B1CB650EAFBQ36260744-0996267D-A330-4F13-8033-1B14D1E4E202Q36497216-6431D20B-C5F2-4B4F-85A1-BE4BF1056A73Q36828335-21E79963-AC47-48AC-82B0-C077F1EA0C80Q38112617-41251764-71FC-46CF-9E3C-FC9F791D249BQ38154393-74A4C24B-9A69-449C-9D0F-F1B7D8C062E2Q38262868-8D6162F5-6A80-41CD-9836-21237039798CQ38616537-8804DAFF-77B4-42FA-88A4-51D8FF7A82B0Q38992291-600099BA-A521-4273-B26C-095BFA9A0943Q42463156-7168015F-BE81-4714-97D5-3AC1E28F6884Q43012357-BF487E81-FB88-468F-9D4D-33AB340B19A2Q48554814-C179BF68-545B-41DD-9420-6C2F84264572Q50428930-34DFE425-C11B-4CED-B274-C9A3500E2967
P2860
description
2012 nî lūn-bûn
@nan
2012 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Treatment of neurodevelopmental disorders in adulthood
@ast
Treatment of neurodevelopmental disorders in adulthood
@en
Treatment of neurodevelopmental disorders in adulthood
@nl
type
label
Treatment of neurodevelopmental disorders in adulthood
@ast
Treatment of neurodevelopmental disorders in adulthood
@en
Treatment of neurodevelopmental disorders in adulthood
@nl
prefLabel
Treatment of neurodevelopmental disorders in adulthood
@ast
Treatment of neurodevelopmental disorders in adulthood
@en
Treatment of neurodevelopmental disorders in adulthood
@nl
P2860
P1476
Treatment of neurodevelopmental disorders in adulthood
@en
P2093
Lamberto Maffei
Randi Hagerman
P2860
P304
14074-14079
P356
10.1523/JNEUROSCI.3287-12.2012
P407
P577
2012-10-01T00:00:00Z